Abstract: Patients with Chronic Kidney Disease (CKD) develop a tendency to bleed and thromboembolism, so the indication for anticoagulants at the attachment of atrial fibrillation (AF) is complex. AF is the most common chronic heart arrhythmia, and thromboembolism and ischemic stroke in particular are the main complications. In recent years, new oral anticoagulants have been developed and they have shown superiority over the classic antivitamin K anticoagulants in preventing the risk of stroke, systemic embolism and bleeding, providing an effective alternative to these resources.